Erythropoiesis after therapy with recombinant human erythropoietin: A dose-response study in anemic cancer surgery patients

Marco Braga, L. Gianotti, O. Gentilini, A. Vignali, L. Corizia, V. Di Carlo

Research output: Contribution to journalArticle

Abstract

Background and Objectives: Preoperative treatment with 600 U/kg of recombinant human erythropoietin (r-HuEPO) effectively increases erythropoiesis in cancer patients. The aim of this study was to evaluate the erythropoietic response after different doses of r-HuEPO in order to find the minimum effective dose. Materials and Methods: Twenty anemic sideropenic patients (hemoglobin ≤ 110 g/l; serum iron <600 μg/l) with cancer of the gastrointestinal tract were randomly allocated to two groups: the first (n = 10) received 400 U/kg of r-HuEPO divided in 4 doses (100 U/kg each, every 4 days); the second (n = 10) received 200 U/kg of r-HuEPO (50 U/kg each, every 4 days). Both groups were given intravenous iron gluconate (125 mg) every day for 15 days. Results: After treatment, the serum iron level significantly rose in both groups. The production of new red blood cells was 176.3 ± 90.8 ml in the 200 U/kg group and 268.4 ± 79.4 ml in the 400 U/kg group (p = 0.036). The increase of hemoglobin was significantly higher in the 400 U/kg group (22.3 ± 2.0 g/l) than in the 200 U/kg group (14.1 ± 2.7 g/l) (p = 0.017). Conclusion: The r-HuEPO dose of 400 U/kg appears significantly more effective than the 200 U/kg to stimulate erythropoiesis in anemic sideropenic cancer patients.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalVox Sanguinis
Volume76
Issue number1
DOIs
Publication statusPublished - Jan 1999

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Erythropoiesis after therapy with recombinant human erythropoietin: A dose-response study in anemic cancer surgery patients'. Together they form a unique fingerprint.

  • Cite this